WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles:
Related suggestion:
Will there be a 'superbloom' this year in California? Here's what to knowAstros rightHong Kong loses ground as top container port amid change in status — Radio Free AsiaMitchell Parker throws 7 scoreless innings as Nats blank Astros 6Oklahoma bus driver crashes into a building after a passenger punches him, police sayLondon Marathon pays tribute to last year's winner Kelvin Kiptum, who died in car crashSarah Jayne Dunn sets pulses racing in animal print bra as she joins chic Georgia May Foote at COMutiso Munyao pulls away from 41An explosion razes a home in Maryland, sending 1 person to the hospitalDanny Dyer 'charges fans nearly £100 for selfie and autograph during meet and greet in Liverpool'
0.0969s , 6574.890625 kb
Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,Culture Cross news portal